SavedAdd your journal

Journals / Türk Kardiyoloji Derneği Arşivi / 2021 / Cilt: 49 - Sayı: 4

Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia

Hipertansiyon prevalansı ve renin-anjiyotensin-aldosteron sistemi blokerleri kullanımının COVID-19 ve COVID-19 dışı viral pnömoni hastalarında karşılaştırılması

Ashok Paudel
Mehmet Erkan Ekicibaşı
Burak Pamukçu
Ceyda Erel Kırışoğlu
Selçuk Görmez
Aleks Değirmencioğlu
Gökçe Akan
Fatmahan Atalar
Nevin Sarıgüzel
Pages
286–292
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Hypertension and CAD were more common in patients with nonCOVID-19 viral pneumonia than in patients with COVID-19 (39.6% vs 22.3%, respectively, p=0.012 and 24.2% vs 4.9%, respectively, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To compare the prevalence of hypertension and pre-existing use of renin-angiotensin-aldosterone system blockers in patients with coronavirus disease (COVID-19) and non-COVID-19 viral pneumonias.
📊
Key Findings & Data:Methods: Real-time polymerase chain reaction confirmed COVID-19 and non-COVID-19 pneumonia patients were retrospectively analyzed.
💡
Conclusion & Impact:Hypertension and CAD were more common in patients with nonCOVID-19 viral pneumonia than in patients with COVID-19 (39.6% vs 22.3%, respectively, p=0.012 and 24.2% vs 4.9%, respectively, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To compare the prevalence of hypertension and pre-existing use of renin-angiotensin-aldosterone system blockers in patients with coronavirus disease (COVID-19) and non-COVID-19 viral pneumonias. Methods: Real-time polymerase chain reaction confirmed COVID-19 and non-COVID-19 pneumonia patients were retrospectively analyzed. The presence of hypertension, coronary artery disease (CAD), and pre-existing use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) were compared between the groups. Results: A total of 103 COVID-19 and 91 non-COVID-19 hospitalized viral pneumonia patients were enrolled. Hypertension and CAD were more common in patients with nonCOVID-19 viral pneumonia than in patients with COVID-19 (39.6% vs 22.3%, respectively, p=0.012 and 24.2% vs 4.9%, respectively, p

Özet

Amaç: COVID-19 ve COVID-19 dışı viral pnömoni hastalarında hipertansiyon prevalansı ve önceden renin-anjiyotensin-aldosteron blokeri kullanımının karşılaştırılmasıdır. Yöntemler: Gerçek-zamanlı polimeraz zincir reaksiyonu (RT-PCR) ile doğrulanmış COVID-19 pnömoni hastaları ile COVID-19 dışı viral pnömoni hastaları retrospektif olarak incelendi. Gruplar arasında hipertansiyon ve koroner arter hastalığı (KAH) varlığı ile önceden anjiyotensin dönüştürücü enzim inhibitörü (ADEİ) ve anjiyotensin reseptör blokeri (ARB) kullanımları karşılaştırıldı. Bulgular: Çalışmaya hastanede yatarak tedavi gören 103 COVID-19 ve 91 COVID-19 dışı viral pnömoni hastası dahil edildi. Hipertansiyon ve KAH, COVID-19 dışı viral pnömoni hastalarında daha sıktı (%39.6’ya karşılık %22.3, sırasıyla, p=0.012 ve %24.2’ye karşılık %4.9, sırasıyla, p

🔖

Cite This Article

Paudel, A., Ekicibaşı, M. E., Pamukçu, B., Kırışoğlu, C. E., Görmez, S., Değirmencioğlu, A., Akan, G., Atalar, F., Sarıgüzel, N. (2022). Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia. Türk Kardiyoloji Derneği Arşivi, Cilt: 49 - Sayı: 4, 286–292. https://ajindex.com/articles/631838

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020
  2. [Crossref] 2. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet 2020
  3. [Crossref] 3. Bernard Stoecklin S, Rolland P, Silue Y, Mailles A, Campese C, Simondon A, et al. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Euro Surveill 2020
  4. pii=2000094. [Crossref] 4. World Health Organization. Available at: https://www.who. int/dg/speeches/detail/who-director-generals-remarks-atthe-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed February 12, 2020). 5. WHO Director-General’s opening remarks at the media briefing on COVID-19: 11 March 2020. March 11, 2020. Available at: https://www.who.int/dg/speeches/detail/whodirector-general-s-opening-remarks-at-themedia-briefingon-covid-19---11-march-2020 (Accessed March 30, 2020). 6. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020
  5. [Crossref] 7. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA 2020
  6. [Crossref] 8. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. China Medical Treatment Expert Group for Covid-19. clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med 2020
  7. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020
  8. [Crossref] 10. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020
  9. e21. [Crossref] 11. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020
  10. [Crossref] 12. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med 2020
  11. [Crossref] 13. Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observation